Get the Stockscreener App
0.0001
9,900%
0.000099
Syros Pharmaceuticals Inc stock is traded at $0.0001, with a volume of 230.
It is up +9,900% in the last 24 hours and down -71.43% over the past month.
See More
Previous Close:
$0.000001
Open:
$0.0001
24h Volume:
230
Relative Volume:
0.03
Market Cap:
$N/A
Revenue:
$386.00K
Net Income/Loss:
$-97.82M
P/E Ratio:
-0.000033
EPS:
-3.0311
Net Cash Flow:
$-100.06M
1W Performance:
-50.00%
1M Performance:
-71.43%
6M Performance:
-80.00%
1Y Performance:
-99.50%
1-Day Range:
$0.0001
$0.0001
1-Week Range:
$0.000001
$0.0005
52-Week Range:
$0.000001
$0.0282
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare SYRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.0001 | 0 | 386.00K | -97.82M | -100.06M | -3.0311 |
VRTX
Vertex Pharmaceuticals Inc
|
445.04 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.48 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.94 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.39 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
MSN Money - MSN
Syros Pharmaceuticals stock (US8719201096): Latest updates and business overview - AD HOC NEWS
Syros Pharmaceuticals Inc (OTCM:SYRS) Stock Earnings Transcripts - GuruFocus
Syros Pharmaceuticals Inc (OTCM:SYRS) Stock Price & 30 Year Financial Data - GuruFocus
Syros Pharmaceuticals stock (US8719201096): Delisting to OTC triggers investor attention - AD HOC NEWS
Acute Myeloid Leukemia Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC Biopharm - Barchart.com
hVIVO plc (OPORF) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Syros Pharmaceuticals, Inc. (0LC7.L) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Stock List: Research Stocks from Around the World - GuruFocus
Polaris Management Co VII L L C Net WorthInsider Trades and Bio as of Apr 21, 2026 - Benzinga
Syros Pharmaceuticals (SYRS) Expected to Announce Quarterly Earnings on Wednesday - Defense World
MSN - MSN
Myelodysplastic Syndrome Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Globe and Mail
Syros to delist from Nasdaq, deregister from SEC - MSN
AKPKD Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | AceLink Therapeutics, Sanofi, DiNAQOR AG, Poxel, AceLink Therapeutics, Regulus Therapeut - The Globe and Mail
Myelodysplastic Syndrome Pipeline Analysis, 2025 by DelveInsight | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, - Barchart.com
Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital - Yahoo Finance
Syros Pharmaceuticals (SYRS) FDA Approvals, PDUFA Dates & Drug Alerts 2025 - MarketBeat
Syros Pharmaceuticals(SYRS) Stock Options Chain | Quotes & News - Moomoo
SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire
SYRS Stock Price, News & Analysis - Stock Titan
Rege Nephro Acquires Tamibarotene Assets from Syros Pharmaceuticals to Advance ADPKD Program - BioPharma APAC
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - PR Newswire
Syros Pharma pulls out of deal with RaQualia - The Pharma Letter
SYRS Stock Price and Chart — OTC:SYRS - TradingView
Syros Pharmaceuticals, Inc.Common Stock (NQ: SYRS - FinancialContent
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Syros Pharmaceuticals | EFFECT: Others - Moomoo
Wondering what's happening in today's after-hours session? - ChartMill
Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com
Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), State Street SPDR S&P 500 ETF Trust (ARCA:SPY) - Benzinga
Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan
Syros Pharmaceuticals stock hits 52-week low at $0.18 amid steep decline - MSN
Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com
Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Investors to Inquire about Securities Investigation - ACCESS Newswire
Odyssey hires Jason Haas as CFO - BioCentury
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
BlossomHill Therapeutics Appoints Geoff Oxnard, M.D., as Chief Medical Officer and Executive Vice President - Business Wire
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com Australia
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals announces major company changes - Investing.com
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance
Syros’s Hopes Dashed As Tamibarotene Flunks Phase III MDS Trial - Citeline News & Insights
TD Cowen Downgrades Syros Pharmaceuticals(SYRS.US) to Hold Rating - Moomoo
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.65%
1.27%
Cap:
|
Volume (24h):